X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (86) 86
adult (66) 66
index medicus (66) 66
middle aged (66) 66
hematology (64) 64
male (56) 56
female (54) 54
leukemia, myeloid, acute - genetics (53) 53
adolescent (49) 49
prognosis (43) 43
oncology (36) 36
young adult (36) 36
leukemia, myeloid, acute - mortality (33) 33
treatment outcome (29) 29
aged (25) 25
abridged index medicus (24) 24
acute myelogenous leukemia (24) 24
acute myeloid-leukemia (23) 23
mutation (23) 23
aml (19) 19
leukemia, myeloid, acute - therapy (19) 19
leukemia, myeloid, acute - drug therapy (18) 18
leukemia, myeloid, acute - diagnosis (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
cancer (15) 15
fms-like tyrosine kinase 3 - genetics (15) 15
kaplan-meier estimate (15) 15
leukemia, myeloid, acute - pathology (15) 15
chemistry (14) 14
normal cytogenetics (14) 14
performing operations (14) 14
survival rate (14) 14
transporting (14) 14
disease-free survival (13) 13
group-b (13) 13
leukemia, myeloid, acute - metabolism (13) 13
younger adults (13) 13
adult patients (12) 12
biomarkers, tumor - genetics (12) 12
chemotherapy (12) 12
leukemia (12) 12
mutations (12) 12
transcription factors - genetics (12) 12
transplantation (12) 12
aged, 80 and over (11) 11
karyotyping (11) 11
metallurgy (11) 11
nuclear proteins - genetics (11) 11
organic chemistry (11) 11
recurrence (11) 11
remission induction (11) 11
risk factors (11) 11
transplantation, homologous (11) 11
acute disease (10) 10
chromosome aberrations (10) 10
dna mutational analysis (10) 10
general tagging of cross-sectional technologies spanning over several sections of the ipc (10) 10
general tagging of new technological developments (10) 10
internal tandem duplication (10) 10
prospective studies (10) 10
stem cells (10) 10
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (10) 10
therapy (10) 10
trial (10) 10
acute myeloid leukemia (9) 9
chemical or physical processes, e.g. catalysis or colloidchemistry (9) 9
cohort studies (9) 9
doors, windows, shutters, or roller blinds in general (9) 9
fixed constructions (9) 9
fixed or movable closures for openings in buildings, vehicles,fences or like enclosures in general, e.g. doors, windows,blinds, gates (9) 9
follow-up studies (9) 9
gene-mutations (9) 9
ladders (9) 9
myelodysplastic syndromes - genetics (9) 9
normal karyotype (9) 9
physical or chemical processes or apparatus in general (9) 9
survival (9) 9
survival analysis (9) 9
their relevant apparatus (9) 9
acute myeloid leukaemia (8) 8
age factors (8) 8
animals (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
colony-stimulating factor (8) 8
core binding factor alpha 2 subunit (8) 8
gene (8) 8
germany (8) 8
hematopoietic stem cell transplantation (8) 8
leukemia, myeloid - genetics (8) 8
medicine & public health (8) 8
mice (8) 8
prognostic-significance (8) 8
runx1 translocation partner 1 protein (8) 8
t (8) 8
aml study-group (7) 7
clinical trials as topic (7) 7
dna-binding proteins - genetics (7) 7
expression (7) 7
favorable prognosis (7) 7
gene expression (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1364 - 1372
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 18, pp. 1909 - 1918
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2499 - 2506
Journal Article
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2016, Volume 95, Issue 12, pp. 1931 - 1942
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2101 - 2107
Journal Article
CHEMISTRY-A EUROPEAN JOURNAL, ISSN 0947-6539, 02/2002, Volume 8, Issue 3, pp. 622 - 631
A variety of palladium on activated carbon catalysts differing in Pd dispersion, Pd distribution, Pd oxidation state. and water content were tested in Heck... 
C-C coupling | ORGANIC-CHEMISTRY | heterogeneous catalysis | SUPPORTED PALLADIUM CATALYSTS | N-HETEROCYCLIC CARBENES | NONAQUEOUS IONIC LIQUIDS | CHEMISTRY, MULTIDISCIPLINARY | ARYLBORONIC ACIDS | PALLADIUM/IMIDAZOLIUM CHLORIDE SYSTEM | CROSS-COUPLING REACTIONS | carbon | C-C | palladium | DEACTIVATED ARYL CHLORIDES
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 29, pp. 3604 - 3610
Journal Article
Synlett, ISSN 0936-5214, 7/2002, Volume 2002, Issue 7, pp. 1118 - 1122
Abstract A specially optimized air-stable Pd on activated carbon catalyst is demonstrated to be a highly active (TON up to 36,000), selective and convenient... 
letter | SYSTEM | HALIDES | ROOM-TEMPERATURE | CHEMISTRY, ORGANIC | catalysis | SUPPORTED PALLADIUM CATALYSTS | TERMINAL ALKYNES | heterogeneous | ARYL BROMIDES | coupling | CROSS-COUPLING REACTIONS | FINE CHEMICALS | aryl halides | CHLORIDES | palladium | EFFICIENT | Heterogeneous | Palladium | Catalysis | Coupling | Aryl halides
Journal Article